热门资讯> 正文
兰修斯获得Lutathera的仿制药竞争对手Bravnesta的批准
2026-09-22 22:39
- The US FDA has granted final approval to Lantheus Holdings' (LNTH) Bravnesta (lutetium Lu 177 dotatate), a bioequivalent to Novartis' (NVS) radiopharmaceutical to Lutathera.
- Bravnesta is used for the treatment of adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
- Bravnesta was approved through the FDA's Abbreviated New Drug Application (ANDA) pathway.
- Earlier in September, Cirium's radioligand therapy Bexlutry (lutetium Lu 177 dotatate) won approval for the same indication. Cirium is in the middle of acquiring Lantheus as part of an $8B deal.
More on Lantheus Holdings
- Lantheus Holdings: Why I Am Exiting Before The Merger Closes
- Lantheus withdraws, resubmits HSR filing for Curium acquisition
- Novartis' Lutathera now facing generic competition from Curium's Bexlutry
- Seeking Alpha’s Quant Rating on Lantheus Holdings
- Historical earnings data for Lantheus Holdings
推荐文章
一周财经日历 | 影响加息大事！9月大小非农数据重磅登场；美光、希音齐放榜！景旺电子、欢创科技等5只新股下周上市
美股前瞻 | 伊朗总统愿推进与美谈判！三大期指齐升；9月劲升36%！Meta创2013年来最佳月度表现；比特币一度重返8.5万美元
一图看懂 | 华夏富时港股高息ETF开启申购！入场门槛为1000港元
美股前瞻 | 联储局再传“鹰声”！美债收益率应声走高，纳指期货跌近1%；中美第八轮经贸磋商达成多项共识；Meta全面押注个人Agent
Q4净利或狂飙逾1000%！美光能否交出”炸裂“财报？三大焦点将影响股价走向
休市提醒：中秋假期来临，港股9月25日（周五）正常开市
华盛早报 | 强劲PMI催高加息预期！纳指回调1%；美财政部拟再回购60亿美元长债；SpaceX总裁套现逾5200万美元
美股前瞻 | 特朗普最新调仓曝光！抛售微软，买入英伟达；Meta科技盛会重磅来袭；高盛、德银齐看多：标普500将冲刺8000点
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
